PDF(Pubmed)
Abstract：
Ankylosing spondylitis (AS) is a challenging disease, characterized by chronic inflammation and structural damage primarily affecting the axial skeleton, while extra-articular manifestations may also appear. This results in the deterioration of patients\' quality of life. Over the past few decades, tumor necrosis factor-α (TNF-α) inhibitors have revolutionized the management of AS, offering substantial relief from symptoms and improving patient outcomes. The aim of this review is to assess the efficacy of TNF-α inhibitors in patients with active AS. A search was performed in the PubMed database using the following keywords: (\"TNF alpha inhibitors\" OR \"anti TNF-a\" OR \"TNF-a inhibitors\" OR \"anti TNF-alpha\" OR \"Etanercept \" OR \"Golimumab\" OR \"Infliximab\" OR \"Certolizumab pegol\" OR \"Adalimumab\") AND \"ankylosing spondylitis\". The search was completed in February 2024, and 35 studies were included in this review following PRISMA guidelines. The findings reveal evidence supporting the efficacy of TNF-α inhibitors in reducing inflammation, preventing structural damage, and enhancing overall well-being in AS patients. Overall, TNF-α inhibitors have emerged as a cornerstone in the therapeutic algorithm against AS with a very satisfactory safety profile.
摘要：
强直性脊柱炎（AS）是一种具有挑战性的疾病，以慢性炎症和主要影响轴向骨骼的结构损伤为特征，而关节外表现也可能出现。这导致患者生活质量的恶化。在过去的几十年里，肿瘤坏死因子-α（TNF-α）抑制剂彻底改变了AS的管理，提供症状的实质性缓解和改善患者的结果。这篇综述的目的是评估TNF-α抑制剂在活动性AS患者中的疗效。在PubMed数据库中使用以下关键字进行搜索：（\"TNFα抑制剂\"或\"抗TNF-a\"或\"TNF-a抑制剂\"或\"抗TNF-α\"或\"Etanercept\"或\"Golimumab\"或\"英夫利昔单抗\"或\"Certolizumabpegol\"或"阿达利单抗\搜索于2024年2月完成，根据PRISMA指南纳入了35项研究。研究结果表明，有证据支持TNF-α抑制剂在减轻炎症方面的功效，防止结构损坏，并提高AS患者的整体幸福感。总的来说,TNF-α抑制剂已成为抗AS治疗方法的基石，具有非常令人满意的安全性。
